0000899243-21-003286.txt : 20210126
0000899243-21-003286.hdr.sgml : 20210126
20210126160509
ACCESSION NUMBER: 0000899243-21-003286
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210126
FILED AS OF DATE: 20210126
DATE AS OF CHANGE: 20210126
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BridgeBio Pharma, Inc.
CENTRAL INDEX KEY: 0001743881
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38533
FILM NUMBER: 21554072
BUSINESS ADDRESS:
STREET 1: 421 KIPLING STREET
CITY: PALO ALTO
STATE: CA
ZIP: 94301
BUSINESS PHONE: (650) 391-9740
MAIL ADDRESS:
STREET 1: 421 KIPLING STREET
CITY: PALO ALTO
STATE: CA
ZIP: 94301
FORMER NAME:
FORMER CONFORMED NAME: BridgeBio Pharma LLC
DATE OF NAME CHANGE: 20180618
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Eidos Therapeutics, Inc.
CENTRAL INDEX KEY: 0001731831
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 463733671
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 101 MONTGOMERY STREET, SUITE 2550
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
BUSINESS PHONE: 650-391-9740
MAIL ADDRESS:
STREET 1: 101 MONTGOMERY STREET, SUITE 2550
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-01-26
0
0001731831
Eidos Therapeutics, Inc.
EIDX
0001743881
BridgeBio Pharma, Inc.
421 KIPLING STREET
PALO ALTO
CA
94301
0
0
1
0
Common Stock
2021-01-26
4
P
0
14428836
A
1000
D
On January 26, 2021, pursuant to the Agreement and Plan of Merger, dated as of October 5, 2020 (the "Merger Agreement"), by and among BridgeBio Pharma, Inc. ("BridgeBio"), Eidos Therapeutics, Inc. ("Eidos"), Globe Merger Sub I, Inc. ("Merger Sub I") and Globe Merger Sub II, Inc. ("Merger Sub II"), Merger Sub I merged with and into Eidos (the "Initial Merger"), with Eidos surviving the Initial Merger, and thereafter Eidos merged with and into Merger Sub II (the "Subsequent Merger" and, together with the Initial Merger, the "Mergers"), with Merger Sub II surviving the Subsequent Merger as an indirect and wholly owned subsidiary of BridgeBio under the name "Eidos Therapeutics, Inc." (the "Surviving Corporation").
(Continued from footnote 1) At the Effective Time, each share of common stock, par value $0.001 per share, of Eidos ("Eidos Common Stock") issued and outstanding immediately prior to the Effective Time (subject to certain exceptions) was converted into the right to receive, at the election of each stockholder of Eidos, (A) 1.85 shares of BridgeBio's common stock ("BridgeBio Common Stock"), par value $0.001 per share (the "Stock Consideration"), or (B) $73.26 in cash (the "Cash Consideration"). As of the Effective Time, all shares of Eidos Common Stock issued and outstanding immediately prior to the Effective Time were cancelled, and all shares of Merger Sub I held by BridgeBio Pharma LLC immediately prior to the consummation of the Initial Merger were converted into shares of the Surviving Corporation in the Mergers. As a result of the Mergers, BridgeBio now owns all of the outstanding shares of common stock of the Surviving Corporation.
Calculation of number of shares give effect to the consummation of the Initial Merger described herein, in which shares of Eidos Common Stock issued and outstanding immediately prior to the Effective Time were cancelled and the 1,000 shares of Merger Sub I held by BridgeBio were converted into an aggregate of 1,000 shares of common stock of the Surviving Corporation.
BridgeBio Pharma, Inc., By: /s/ Neil Kumar, Chief Executive Officer
2021-01-26